



Unsuccessful Identification of Mutations in Genes Involving the RAS-MAPK Pathway 
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Kabuki (Niikawa-Kuroki) syndrome (KS) is a multiple congenital anomaly/mental 
retardation (MCA/MR) syndrome characterized by long palpebral fissures with eversion of 
the lower eyelids, skeletal anomalies, persistence of fingerpads, short stature, joint laxity, and 
occasional immune abnormalities.  Previous molecular cytogenetic approaches including 
fluorescence in situ hybridization and whole-genome CGH microarray analysis failed to find 
copy-number changes in the genome of KS patients.  Recently, germline mutations in 
PTPN11/KRAS/SOS1/RAF1, HRAS, and KRAS/BRAF/MEK1/MEK2 were shown to be causes 
of Noonan syndrome, Costello syndrome and cardio-facio-cutaneous syndrome, respectively.  
Since KS patients share some phenotypical manifestations with the syndromes above, we 
hypothesized that KS may be associated with mutations in genes involving the RAS-MAPK 
pathway.  Sixteen genes (PTPN11, GRB2, SOS1, HRAS, ERAS, NRAS, KRAS, ARAF, BRAF, 
RAF1, MEK1, MEK2, RASA1, RASA2, RASA3, and RASA4) in the pathway were screened for 
mutations.  DNA from 30 KS patients (14 females and 16 males) was sequenced for entire 
coding regions and splice junctions of the 16 genes.  We identified 29 base substitutions in 
the genes, including 9 nonsynonymous changes, 18 synonymous changes, one in 5’ 
untranslated region and one at position “-4” in splice acceptor site.  But they were almost all 
confirmed as SNPs listed in the NCBI database or found in 82-89 normal Japanese individuals, 





Kabuki (make-up) syndrome (KS, OMIM 147920) also known as Niikawa-Kuroki 
syndrome, is a multiple congenital anomaly/mental retardation (MCA/MR) syndrome 
characterized by a peculiar facial appearance, skeletal abnormalities, joint hypermobility; 
dermatoglyphic abnormalities, postnatal growth retardation, occasional visceral anomalies 
and immune abnormalities.  The cause of KS remains unknown, even though a large number 
of patients from a variety of ethnic groups have been reported since 1981.  The prevalence 
was estimated to be 1/32,000 in Japan [Niikawa et al., 1988] and 1/86,000 in Australia and 
New Zealand [White et al., 2004].  Although most cases were sporadic, at least 14 familial 
cases have been reported.  The equal male-to-female ratio of patients, and parent-child 
transmissions in some familial cases suggest an autosomal dominant of inheritance [Niikawa 
et al., 1988; Matsumoto and Niikawa, 2003].  At least six autosomal structural abnormalities 
have been reported in patients with KS or KS-like features [Matsumoto and Niikawa, 2003], 
but no concordant specific cytogenetic lesion have been found.  Studies with microarray 
comparative genomic hybridization (CGH) on karyotypically normal patients did not find any 
pathological genome-copy changes [Hoffman et al., 2005; Schoumans et al., 2005; Miyake et 
al., 2006].  Disrupted C20orf133 gene with a patient with KS was reported, but the 





Recently, germline mutations in some genes involving the Ras-mitogen-activated 
protein kinase (RAS-MAPK) signal transduction pathway have been shown to be causes of 
multiple congenital anomaly syndromes; i.e. PTPN11, KRAS, SOS1 and RAF1 in Noonan 
syndrome [Tartaglia et al., 2001; Schubbert et al., 2006; Roberts et al., 2006; Tartaglia et al., 
2006, Pandit et al., 2007; Razzaque et al., 2007], HRAS in Costello syndrome [Aoki et al., 
2005], and KRAS, BRAF, MEK1 and MEK2 in cardio-facio-cutaneus (CFC) syndrome 
[Niihori et al., 2006; Rodriguez-Viciana et al., 2006].  Since KS patients share some clinical 
manifestations with Noonan/Costello/CFC syndromes, we hypothesized that KS may be 
associated with mutations in a gene involving the RAS-MAPK pathway.  To test the 
hypothesis, we screened in 30 KS patients for mutations in 16 genes involving the 
RAS-MAPK pathway. 
 
MATERIALS AND METHODS 
Subjects 
The subjects involved in this study consisted of 30 KS patients (14 females, 16 males). 
Genomic DNA was extracted from their peripheral blood leukocytes or from 
EBV-transformed lymphoblastoid cells established after obtaining informed consent from all 
subjects and/or their parents.  Two phenotypically and karyotypically normal individuals 




approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis in 
Nagasaki University. 
The 16 genes selected for mutation analysis were the following: NRAS (located to 
1p13.2), SOS1 (2p22.1), RASA2 (3p23), RAF1 (3p25), RASA1 (5q13.3), RASA4 (7q22.1), 
BRAF (7q34), HRAS (11p15.5), KRAS (12p12.1), PTPN11 (12q24.13), RASA3 (13q34), 
MEK1 (15q22.31), GRB2 (17q25.1), MEK2 (19p11.3), ERAS (Xp11.23) and ARAF (Xp11.23).  
Genomic sequences were retrieved from the UCSC genome browser (assembly: Mar, 2006; 
http://genome.ucsc.edu/).  
Mutation Search 
We sequenced the entire coding region and splice junctions of the genes in the 30 
patients and two controls.  Primer sequences are available on request. PCR was carried out 
in a final volume of 10 l, containing 10 ng of genomic DNA, 0.5 M each primer, 200 M 
dNTP, 0.05 Units TaKaRa ExTaq HS version (TaKaRa, Kyoto, Japan) and 1x PCR buffer with 
conditions of initial incubation at 94 °C for 2 min followed by cycles of denaturation at 94 °C 
for 30 sec, annealing at 56-64 °C for 30 sec, extension at 72 °C for 30-45 sec, and final 
extension at 72 °C for 5 min. Amplification of the first exon of MEK1 required use of special 
buffer, containing DMSO, MgCl2, NH4SO4, and -mercaptoethanol.  To amplify the first 
exon of BRAF, we performed nested PCR with the use of above-mentioned special buffer.  A 




Amplification of the first exon of RASA2 and the first exon of MEK2 required DNA 
polymerase special for high GC content sequence (AccuPrime
TM
, Invitrogen, Carlsbad, CA).  
PCR products were cleaned up with ExoSAP-IT (Amersham Biosciences, NJ) following the 
instruction manual, and sequenced directly using BigDye sequencing kit ver.3.1 (Applied 
Biosystems).  Sequenced samples were purified with SephadexG-50 (Amersham 
Biosciences) and run on an automated sequencer Model 3100 (Applied Biosystems).  
Resultant electropherograms were analyzed by DNA Sequencing Analysis software version 
3.7 (PE Applied Biosystems), and were aligned using ATGC v3.0 (Software Development, 
Tokyo, Japan) and inspected visually to find DNA alterations. 
 
RESULTS AND DISCUSSION 
In the 16 genes analyzed in 30 patients with KS, we found 29 base substitutions (Table 
I).  Nine base substitutions in the coding regions lead to nonsynonymous amino acid changes.  
Two of them were confirmed as SNPs listed in the NCBI database, and five of them were 
found in 85 or 88 normal Japanese individuals.  Two of them were not found in the normal 
controls, but each mutation was detected in only one patient.  Eighteen base substitutions in 
the coding regions lead to synonymous amino acid changes.  Thirteen of them were found in 
dbSNP, and three of them were found in 85 or 89 normal Japanese individuals, while two of 




5’untranslated region and another is around the splice donor site. 
It is less likely that a large scale genomic rearrangement is the common cause of KS, 
since array-based comparative genome hybridization (array-CGH) did not detect any 
abnormality in previously reported 8p22-p23.1, and in whole genome with 1.2/1.5 megabase 
resolution [Hoffman et al., 2005; Schoumans et al., 2005; Miyake et al., 2006].  Although 
Maas et al. [2007] reported a de novo deletion of the exon 5 region in C20orf133 gene with a 
patient with KS, they failed to detect mutations or copy number changes of the gene in 19 
additional patients with KS.  The deleted region might be a rare copy-number variation 
because the region was in common with a normal loss [Pinto et al., 2007] registered in 
Database of Genomic Variants (http://projects.tcag.ca/variation/). 
Recently, germline mutations in the RAS-MAPK pathway have been shown to a cause 
of Noonan, Costello, and CFC syndromes [Tartaglia et al., 2001; Aoki et al., 2005; Schubbert 
et al., 2006; Niihori et al., 2006; Rodriguez-Viciana et al., 2006].  These achievements 
encouraged us that a disturbance of certain transcriptional factors or oncogenes related to the 
pathway may cause KS as an MCA syndrome due to their variety functions, and we picked up 
the genes.  
Mutations in RASA1, most of them results in premature termination codon, are known 
as a cause of capillary malformation-arteriovenous malformation (CM-AVM) [Boon LM, et 




is not a definitive evidence to confirm RASA1 gene is the responsible for KS.  We also 
cannot find copy number change in RASA1 gene by quantitative PCR (data not shown).  In 
conclusion, no pathogenic mutations were detected in any of the genes analyzed and in any of 
the patients examined. 
KS is a clear clinical entity with a recognizable facial gestalt, it also has a variety of 
other manifestations, such as vertebral, visceral, ectodermal and connective tissue, and 
sometimes immunological abnormalities [Matsumoto and Niikawa, 2003; Hoffman et al., 
2005].  So many various clinical manifestations make it difficult to speculate rationally a 
candidate gene.  Some KS patients have characteristic lower lip pits [Niikawa et al., 1988; 
Makita et al., 1999; Matsumoto and Niikawa, 2003] which is a common and specific finding 
of Van der Woude syndrome associated with haploinsufficiency of the IRF6 gene [Kondo et 
al., 2002].  The IRF-6 has an SMIR domain interacting with Smads that act as a component 
of transcriptional factor complex activated by serine/threonine phosphorylation by 
transforming growth factor  receptors (TGFBRs) [Shi and Massague, 2003].  It is 
speculated that TGF- signaling may regulate IRF-6 as does for IRF-7 [Qing et al., 2004].  
These findings suggested that IRF6 was a candidate gene causative for KS [Armstrong et al., 
2005].  Bottani et al. [2006] added transforming growth factor  receptors (TGFBR) 1 and 
TGFBR2 to candidate genes.  They screened for mutations and copy number changes of the 




It remains to be seen whether mutations are found in KS patients in genes involving the 
TGF- and INF signaling pathways.  We may need to perform an intensive PCR-based 
mutation search in these genes. 
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TABLE I. Nucleotide changes found in 15 genes involving in the RAS-MAPK pathway in 30 
patients with Kabuki syndrome 
 Gene Change of Number of  SNP ID Allele 
  Nucleotide Amino Acid patients Frequency 
Non- RASA1 c.73G>A A26T 1 NR 0.000* 
Synonymous  c.473C>G S158C 1 NR 0.000* 
 RASA4 c.379T>C W127R 7 NR 0.800† 
  c.381G>C W127R 9 NR 0.900† 
  c.401G>A R134Q 12 NR 0.806† 
  c.674T>C V225A 6 NR 0.051‡ 
  c.728G>A R243Q 7 NR 0.063‡ 
  c.1054A>G M352V 8 rs746316  
  c.1103T>C L368P 4 rs886343 
Synonymous SOS1 c.195A>C R65R 1 NR 0.045§ 
  c.1230G>A Q410Q 1 NR 0.000# 
 BRAF c.1689C>G G563G 1 NR 0.000† 
 RASA4 c.330C>T V110V 22 NR 0.847†  
  c.336C>T P112P 25 NR 0.847† 
 KRAS c.519T>C D173D 10 rs1137282  
 
  
 HRAS c.81T>C H27H 9 rs2227994  
 BRAF c.1929A>G G643G 4 rs1042179  
 RAF1 c.1929A>G T543T 1 rs5746244  
 MEK2 c.453C>T D151D 5 rs17851657  
  c.660C>A I220I 20 rs11539507  
 RASA1 c.3067T>C L1023L 3 rs3747704  
 RASA2 c.2028T>C N672N 16 rs295322  
  c.2172G>A L720L 18 rs295323  
 RASA3 c.1326T>C T442T 12 rs2274717  
 RASA4 c.339T>C D113D 4 rs11547191 
  c.1512C>T A504A 3 rs739735  
  c.2253C>T G751G 7 rs3099742  
Others RASA4 IVS17+4C>T intron17 2 NR 0.057** 
 NRAS -208T>A 5’UTR 4 rs2273267 
 
A, Allele frequency among normal Japanese; NR, not registered in NCBI database 
*, not found in 86 control Japanese individuals; †, found in the 85 controls; ‡, found in the 88 
controls; §, found in the 89 controls; #, not found in the 82 controls; **, found in the 87 
controls; ††, 5’UTR 
